


10/523444

Doc # PCT/SG 31 JAN 2005

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50304/059001		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.		To Be Assigned		
		Applicant		GILLES et al.		
		Filing Date		January 31, 2005		
		Group		To Be Assigned		
		IDS Filed		January 31, 2005		
(37 CFR §1.98(b))						
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
/MS/	WO 99/58680	11/18/1999	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
/MS/	Genbank accession number: AAW27416 corresponding to the International Application WO9710354-A1 (Kyowa Hakko Kogyo KK). 20.03.97.					
	Genbank accession number: AAR52526 corresponding to the European Application EP592106-A1 (Immunogen Inc.) 13.04.94.					
	Genbank accession number: AX417628 corresponding to the International Application WO231510 (PEPSCCAN SYSTEMS BV) 18.06.02.					
	Genbank accession number: AR144014 corresponding to the U.S. Application US6210671 (Protein Design Labs, Inc.) 03-04.01.					
	Genbank accession number: AAT38510 corresponding to the International Application WO9632495-A1 (LG Chem. Ltd.) 06.04.96					
	Gilles et al., "Antibodies to Idiotypes of Human Monoclonal Antifactor VIII (FVIII) Antibodies Neutralise Their Inhibitory Activity," Blood 94 (Suppl. 10, Part 1):460, abstract 2048 (1999)					
	Gilles et al., "Neutralization Antiidiotypic Antibodies to Factor VIII Inhibitors After Desensitization in Patients with Hemophilia A," J. Clin. Invest. 97:1382-1388 (1996)					
	Jacquemin, "Mechanism and Kinetics of Factor VIII Inactivation: Study With an IgG4 Monoclonal Antibody Derived from a Hemophilia A Patient With Inhibitor," Blood 92:496-506 (1998)					
	Lubahn and Reisner, "Characterization of a Monoclonal Anti-Idiotypic Antibody to Human Anti-Factor VIII Antibodies," Proc. Natl. Acad. Sci. USA 87:8232-8236 (1990)					
/MS/	Saint-Remy, "Anti-Idiotypic Antibodies: From Regulation to Therapy of Factor VIII Inhibitors," Vox Sang 77 (supp 1):21-24 (1999)					
EXAMINER			/Michael Szperka/			
DATE CONSIDERED			08/28/2007			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/059001
	Serial No.	10/523,444
	Applicant	Gilles et al.
	Filing Date	Jan. 31, 2005
	Group	1641
	IDS Filed	September 15, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
/MS/	WO 99/58680	11/18/99	WIPO			
/MS/	WO 01/04269	01/18/01	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
/MS/	Algiman et al., "Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals," <i>Proceedings of the National Academy of Sciences USA</i> 89: 3795-3799 (1992).					
	Gilles et al., "Antibodies to idiotypes of human monoclonal anti-factor VIII (FVIII) antibodies neutralise their inhibitory activity," <i>Blood</i> , 94(10 Suppl. 1 Part 1) 460a, Abstract# 2048 (1999-11-15).					
	Gilles et al., "Anti-factor VIII Antibodies of Hemophilic Patients are Frequently Directed Towards Nonfunctional Determinants and Do Not Exhibit Isotypic Restriction," <i>Blood</i> 82(8): 2452-2461 (1993).					
	Gilles et al., "Healthy Subjects Produce both Anti-Factor VIII and Specific Anti-Idiotypic Antibodies," <i>Journal of Clinical Investigation</i> 94(4): 1496-1505 (1994).					
	Gilles et al., "Neutralizing Antiidiotypic Antibodies to Factor VIII Inhibitors after Desensitization in Patients with Hemophilia A," <i>Journal of Clinical Investigation</i> 97(6): 1382-1388 (1996).					
	Jacquemin et al., "A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor," <i>Blood</i> 95(1): 156-163 (2000).					
	Jacquemin et al., "Mechanism and Kinetics of Factor VIII Inactivation: Study With an IgG4 Monoclonal Antibody Derived From a Hemophilia A Patient With Inhibitor" <i>Blood</i> 92(2): 496-506 (1998).					
	Kaufman et al., "Synthesis, Processing, and Secretion of Recombinant Human Factor VIII Expressed in Mammalian Cells," <i>The Journal of Biological Chemistry</i> 263(13): 6352-6362 (1988).					
	Lenting et al., "The Light Chain of Factor VIII Comprises a Binding Site for Low Density Lipoprotein Receptor-related Protein," <i>The Journal of Biological Chemistry</i> 274(34): 23734-23739 (1999).					
/MS/	Lubahn et al., "Characterization of a monoclonal anti-Idiotypic antibody to human anti-factor VIII antibodies,"					
EXAMINER			/Michael Szperka/			
DATE CONSIDERED			08/28/2007			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/059001
<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p>		Serial No.	10/523,444
		Applicant	Gilles et al.
		Filing Date	Jan. 31, 2005
		Group	1641
		IDS Filed	September 15, 2006
(37 C.F.R. § 1.98(b))			

	<i>Proceedings of the National Academy of Sciences USA 87: 8232-8236 (1990).</i>
/MS/	Manivel et al., "Maturation of an Antibody Response Is Governed by Modulations in Flexibility of the Antigen-Combining Site," <i>Immunity</i> 13: 611-620 (2000).
	Pratt et al., "Structure of the C2 domain of human factor VIII at 1.5 Å resolution," <i>Nature</i> 402: 439-442 (1999).
	Saenko et al., "Role of the Low Density Lipoprotein-related Protein Receptor in Mediation of Factor VIII Catabolism," <i>The Journal of Biological Chemistry</i> 274(53): 37685-37692 (1999).
	Saint-Remy et al., "Anti-Idiotypic antibodies: From Regulation to Therapy of Factor VIII Inhibitors," <i>Vox Sanguinis</i> , S. Karger AG, Basel, CH, 77(Suppl. 1): 21-24 (1999).
	Singh et al., "Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model," <i>Blood</i> 99(9): 3235-3240 (2002).
	Spiegel Jr. et al., "Structure of a factor VIII C2 domain-immunoglobulin G4x Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII," <i>Blood</i> 98(1): 13-19 (2001).
	Van den Brink et al., "Two classes of germline genes both derived from the V _H 1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII," <i>Blood</i> 99(8): 2828-2834 (2002).
	Wilbur et al., "Rapid similarity searches of nucleic acid and protein data banks," <i>Proceedings of the National Academy of Sciences USA</i> 80: 726-730 (1983).
	International Search Report issued in PCT/EP03/08365 (dated December 4, 2003)
	International Preliminary Examination Report issued in PCT/EP03/08365 (dated August 17, 2004)
	International Preliminary Examination Report issued in PCT/EP03/08365 (dated September 21, 2004)
	Genebank accession number: AAW27416 corresponding to the international application WO9710354 (Kyowa Hakko Kogyo KK). 20-03-1997
	Genebank accession number: AAR52526 corresponding to the European application EP592106 (Immunogen Inc.) 13-04-1994
	Genebank accession number: AX417628 corresponding to the international application number WO231510 (PEPSCAN SYSTEMS BV) (NL) 18-06-2002.
	Genebank accession number: AR144014 corresponding to the U.S. patent US6210671-A/3 (Protein Design Labs, Inc.) 03-04-2001
/MS/	Genebank accession number: AAT38510 corresponding to the international application WO9632495-A/1 (LG Chem Ltd.) 06-04-1996

EXAMINER /Michael Szperka/	DATE CONSIDERED 08/28/2007
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10523444
Filing Date	2005-01-31
First Named Inventor	GILLES et al.
Art Unit	1644
Examiner Name	TBA
Attorney Docket Number	50304/059001

U.S.PATENTS

[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S.PATENT APPLICATION PUBLICATIONS

[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

[Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10523444
Filing Date	2005-01-31
First Named Inventor	GILLES et al.
Art Unit	1644
Examiner Name	TBA
Attorney Docket Number	50304/059001

/MS/	1	Jacquemin et al. "Mechanism and Kinetics of Factor VIII Inactivation: Study with an IgG4 Monoclonal Antibody Derived From a Hemophilia A Patient With Inhibitor," Blood 92(2):496-506 (1998).	<input type="checkbox"/>
/MS/	2	Sultan et al., "Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies," Proc. Natl. Acad. Sci. USA 84:828-831 (1987).	<input type="checkbox"/>
/MS/	3	EPO Communication pursuant to Article 96(2) EPC (EP Application No. 03 784 106.1 - 1222), dated October 10, 2006.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Michael Szperka/	Date Considered	08/28/2007
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.